Older breast cancer patients undergoing immunotherapy experience similar rates of immune-related adverse events as younger patients. However, older patients had higher rates of nephritis, while younger patients had higher rates of transaminitis and higher-grade hypothyroidism. Older patients also required more interruptions in immunotherapy due to toxicity and a higher level of steroid use for management of adverse events. The study, conducted at an academic institution, suggests that more research is needed to validate these findings and help with clinical decision-making for older adults receiving immunotherapy for breast cancer. The study was presented at the San Antonio Breast Cancer Symposium by Neelima Vidula, MD, and colleagues.
Source link
Safety profiles with immunotherapy similar among older, younger patients with breast cancer
